Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2034862875', 'doi': 'https://doi.org/10.1080/10428190801896103', 'title': 'Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib', 'display_name': 'Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib', 'publication_year': 2008, 'publication_date': '2008-01-01', 'ids': {'openalex': 'https://openalex.org/W2034862875', 'doi': 'https://doi.org/10.1080/10428190801896103', 'mag': '2034862875', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/18398720'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1080/10428190801896103', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S27064115', 'display_name': 'Leukemia & lymphoma/Leukemia and lymphoma', 'issn_l': '1026-8022', 'issn': ['1026-8022', '1029-2403', '1042-8194'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320547', 'host_organization_name': 'Taylor & Francis', 'host_organization_lineage': ['https://openalex.org/P4310320547'], 'host_organization_lineage_names': ['Taylor & Francis'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'review', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5008651904', 'display_name': 'Oliver Hantschel', 'orcid': 'https://orcid.org/0000-0001-8569-8169'}, 'institutions': [{'id': 'https://openalex.org/I138211613', 'display_name': 'Austrian Academy of Sciences', 'ror': 'https://ror.org/03anc3s24', 'country_code': 'AT', 'type': 'government', 'lineage': ['https://openalex.org/I138211613']}], 'countries': ['AT'], 'is_corresponding': False, 'raw_author_name': 'Oliver Hantschel', 'raw_affiliation_strings': ['CeMM Center for Molecular Medicine of the Austrian Academy of Sciences Vienna, Austria.'], 'affiliations': [{'raw_affiliation_string': 'CeMM Center for Molecular Medicine of the Austrian Academy of Sciences Vienna, Austria.', 'institution_ids': ['https://openalex.org/I138211613']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5012452779', 'display_name': 'Uwe Rix', 'orcid': 'https://orcid.org/0000-0002-8242-2770'}, 'institutions': [{'id': 'https://openalex.org/I138211613', 'display_name': 'Austrian Academy of Sciences', 'ror': 'https://ror.org/03anc3s24', 'country_code': 'AT', 'type': 'government', 'lineage': ['https://openalex.org/I138211613']}, {'id': 'https://openalex.org/I4210127611', 'display_name': 'CeMM Research Center for Molecular Medicine', 'ror': 'https://ror.org/02z2dfb58', 'country_code': 'AT', 'type': 'facility', 'lineage': ['https://openalex.org/I138211613', 'https://openalex.org/I4210127611']}], 'countries': ['AT'], 'is_corresponding': False, 'raw_author_name': 'Uwe Rix', 'raw_affiliation_strings': ['CeMM-Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090, Vienna, Austria'], 'affiliations': [{'raw_affiliation_string': 'CeMM-Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090, Vienna, Austria', 'institution_ids': ['https://openalex.org/I138211613', 'https://openalex.org/I4210127611']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5069216326', 'display_name': 'Giulio Superti‐Furga', 'orcid': 'https://orcid.org/0000-0002-0570-1768'}, 'institutions': [{'id': 'https://openalex.org/I138211613', 'display_name': 'Austrian Academy of Sciences', 'ror': 'https://ror.org/03anc3s24', 'country_code': 'AT', 'type': 'government', 'lineage': ['https://openalex.org/I138211613']}, {'id': 'https://openalex.org/I4210127611', 'display_name': 'CeMM Research Center for Molecular Medicine', 'ror': 'https://ror.org/02z2dfb58', 'country_code': 'AT', 'type': 'facility', 'lineage': ['https://openalex.org/I138211613', 'https://openalex.org/I4210127611']}], 'countries': ['AT'], 'is_corresponding': False, 'raw_author_name': 'Giulio Superti-Furga', 'raw_affiliation_strings': ['CeMM-Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090, Vienna, Austria'], 'affiliations': [{'raw_affiliation_string': 'CeMM-Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090, Vienna, Austria', 'institution_ids': ['https://openalex.org/I138211613', 'https://openalex.org/I4210127611']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 2, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 3.015, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 245, 'citation_normalized_percentile': {'value': 0.998211, 'is_in_top_1_percent': True, 'is_in_top_10_percent': True}, 'cited_by_percentile_year': {'min': 98, 'max': 99}, 'biblio': {'volume': '49', 'issue': '4', 'first_page': '615', 'last_page': '619'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11215', 'display_name': 'Efficacy and Resistance in CML Treatment', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11215', 'display_name': 'Efficacy and Resistance in CML Treatment', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11157', 'display_name': 'Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia', 'score': 0.9986, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10185', 'display_name': 'Lymphoid Neoplasms', 'score': 0.9902, 'subfield': {'id': 'https://openalex.org/subfields/2734', 'display_name': 'Pathology and Forensic Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/imatinib', 'display_name': 'Imatinib', 'score': 0.508222}, {'id': 'https://openalex.org/keywords/therapeutic-targets', 'display_name': 'Therapeutic Targets', 'score': 0.507767}, {'id': 'https://openalex.org/keywords/ponatinib', 'display_name': 'Ponatinib', 'score': 0.44588766}], 'concepts': [{'id': 'https://openalex.org/C2777413986', 'wikidata': 'https://www.wikidata.org/wiki/Q412327', 'display_name': 'Nilotinib', 'level': 4, 'score': 0.9841931}, {'id': 'https://openalex.org/C2779536868', 'wikidata': 'https://www.wikidata.org/wiki/Q419940', 'display_name': 'Dasatinib', 'level': 4, 'score': 0.9434005}, {'id': 'https://openalex.org/C2777583451', 'wikidata': 'https://www.wikidata.org/wiki/Q177094', 'display_name': 'Imatinib', 'level': 3, 'score': 0.89690566}, {'id': 'https://openalex.org/C2778729363', 'wikidata': 'https://www.wikidata.org/wiki/Q11688946', 'display_name': 'Myeloid leukemia', 'level': 2, 'score': 0.71747255}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.6011377}, {'id': 'https://openalex.org/C42362537', 'wikidata': 'https://www.wikidata.org/wiki/Q87099740', 'display_name': 'Tyrosine kinase', 'level': 3, 'score': 0.5997695}, {'id': 'https://openalex.org/C2778820342', 'wikidata': 'https://www.wikidata.org/wiki/Q906415', 'display_name': 'Tyrosine-kinase inhibitor', 'level': 3, 'score': 0.5166609}, {'id': 'https://openalex.org/C2780381907', 'wikidata': 'https://www.wikidata.org/wiki/Q198728', 'display_name': 'Ponatinib', 'level': 5, 'score': 0.44588766}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.43310672}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.43054736}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.372944}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.32387483}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.088519245}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.06747252}], 'mesh': [{'descriptor_ui': 'D016503', 'descriptor_name': 'Drug Delivery Systems', 'qualifier_ui': 'Q000379', 'qualifier_name': 'methods', 'is_major_topic': True}, {'descriptor_ui': 'D016044', 'descriptor_name': 'Fusion Proteins, bcr-abl', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': True}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D001549', 'descriptor_name': 'Benzamides', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069439', 'descriptor_name': 'Dasatinib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016503', 'descriptor_name': 'Drug Delivery Systems', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016044', 'descriptor_name': 'Fusion Proteins, bcr-abl', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068877', 'descriptor_name': 'Imatinib Mesylate', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': False}, {'descriptor_ui': 'D010879', 'descriptor_name': 'Piperazines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011743', 'descriptor_name': 'Pyrimidines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013844', 'descriptor_name': 'Thiazoles', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1080/10428190801896103', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S27064115', 'display_name': 'Leukemia & lymphoma/Leukemia and lymphoma', 'issn_l': '1026-8022', 'issn': ['1026-8022', '1029-2403', '1042-8194'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320547', 'host_organization_name': 'Taylor & Francis', 'host_organization_lineage': ['https://openalex.org/P4310320547'], 'host_organization_lineage_names': ['Taylor & Francis'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/18398720', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.69, 'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 17, 'referenced_works': ['https://openalex.org/W1970962784', 'https://openalex.org/W1972844855', 'https://openalex.org/W1986139301', 'https://openalex.org/W1991795177', 'https://openalex.org/W2004492241', 'https://openalex.org/W2009654306', 'https://openalex.org/W2014582878', 'https://openalex.org/W2026542427', 'https://openalex.org/W2031594339', 'https://openalex.org/W2066099870', 'https://openalex.org/W2090004346', 'https://openalex.org/W2092606584', 'https://openalex.org/W2107268345', 'https://openalex.org/W2124196948', 'https://openalex.org/W2143877481', 'https://openalex.org/W2161835431', 'https://openalex.org/W2168691181'], 'related_works': ['https://openalex.org/W4283524715', 'https://openalex.org/W34826755', 'https://openalex.org/W2802017747', 'https://openalex.org/W2360725119', 'https://openalex.org/W2314058894', 'https://openalex.org/W2163329109', 'https://openalex.org/W2150962457', 'https://openalex.org/W2056917031', 'https://openalex.org/W2025422981', 'https://openalex.org/W2008126849'], 'abstract_inverted_index': {'Following': [0], 'the': [1, 24, 28, 36, 40, 44, 56], 'initial': [2], 'success': [3], 'of': [4, 30, 43], 'imatinib': [5], 'as': [6], 'frontline': [7], 'therapy': [8], 'for': [9], 'chronic': [10], 'myeloid': [11], 'leukemia': [12], '(CML),': [13], 'several': [14], 'second-generation': [15], 'therapeutics': [16], 'have': [17], 'been': [18], 'developed': [19], 'with': [20], 'increased': [21], 'potency': [22], 'and': [23, 49], 'ability': [25], 'to': [26, 53], 'inhibit': [27], 'majority': [29], 'imatinib-resistant': [31], 'mutations.': [32], 'Here,': [33], 'we': [34], 'review': [35], 'current': [37], 'knowledge': [38], 'about': [39], 'target': [41], 'specificity': [42], 'two': [45], 'new': [46], 'inhibitors': [47], 'nilotinib': [48], 'dasatinib': [50], 'in': [51], 'comparison': [52], 'imatinib,': [54], 'including': [55], 'recent': [57], 'large-scale': [58], 'chemical': [59], 'proteomics': [60], 'screens.': [61]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2034862875', 'counts_by_year': [{'year': 2024, 'cited_by_count': 6}, {'year': 2023, 'cited_by_count': 13}, {'year': 2022, 'cited_by_count': 12}, {'year': 2021, 'cited_by_count': 15}, {'year': 2020, 'cited_by_count': 23}, {'year': 2019, 'cited_by_count': 10}, {'year': 2018, 'cited_by_count': 16}, {'year': 2017, 'cited_by_count': 19}, {'year': 2016, 'cited_by_count': 11}, {'year': 2015, 'cited_by_count': 17}, {'year': 2014, 'cited_by_count': 11}, {'year': 2013, 'cited_by_count': 19}, {'year': 2012, 'cited_by_count': 22}], 'updated_date': '2024-09-24T15:31:39.363461', 'created_date': '2016-06-24'}